- BD launches needle aimed at diabetics
- FDA clears Novo Nordisk insulin pen for children
- Eat Well, Test Well: Bayer HealthCare and dLife Healthcare Solutions launch diabetes resource
- Study: Type 2 diabetes market competition heats up amid disease rate increase
- Three new Takeda diabetes drugs become available
JERUSALEM Oramed Pharmaceuticals has seen promising results from a clinical trial of an oral insulin for diabetes, the Israeli drug maker said.
The company said its exploratory clinical trial of the oral insulin capsule ORMD-0801 was successful. The company is developing the capsule as a treatment for patients with uncontrolled Type 1 diabetes. The company also is developing the oral insulin as a treatment for Type 2 diabetes.
“This study marks an impressive milestone for Oramed,” CEO Nadav Kidron said. “These results suggest a possible novel and unique indication for our oral insulin product in the treatment of Type 1 diabetes in addition to our main indication for Type 2 diabetes.”